ACA vs VATE: stock comparison and AI forecast
Arcosa, Inc. (ACA) and Innovate Corp. (VATE) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
ACA Arcosa, Inc.
- Price
- $149.15 +28.1% · 6M
- Market Cap
- $7.32B
- P/E Ratio
- 15.4x
- Size
- mid-cap
- AI Forecast
- NO CURRENT FORECAST
VATE Innovate Corp.
- Market Cap
- $68M
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- ACA is 108.0 times larger than VATE by market capitalization ($7.32B against $68M).
- ACA turns 17.9% of its revenue into net income, against -1.5% for VATE.
- VATE yields 2.65% in dividends and ACA 0.14%.
- Both companies share the SEC industry classification Fabricated Structural Metal Products.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | ACA | VATE |
|---|---|---|
| Market Cap | $7.32B | $68M |
| P/E Ratio | 15.39x | – |
| P/B Ratio | 2.46x | – |
| Dividend Yield | 0.14% | 2.65% |
| EPS | $9.69 | $-1.86 |
| Book Value/Share | $60.75 | – |
| Revenue/Share | $55.90 | $111.14 |
| FCF/Share | $2.75 | $10.64 |
Profitability & Margins
| Metric | ACA | VATE |
|---|---|---|
| ROE | 16.5% | – |
| ROA | 9.3% | -2.2% |
| ROIC | 6.7% | -84.6% |
| Gross Margin | 23.0% | 15.9% |
| Operating Margin | 11.8% | 4.3% |
| Net Margin | 17.9% | -1.5% |
| EBT Margin | 8.3% | -1.0% |
| Tax Rate | 13.1% | -49.0% |
Financial Health
| Metric | ACA | VATE |
|---|---|---|
| Current Ratio | 3.12x | 0.44x |
| Quick Ratio | 2.31x | 0.43x |
| D/E Ratio | 0.78x | – |
| Financial Leverage | 1.78x | – |
| Interest Coverage | 3.6x | 19.2x |
| Working Capital | $959M | -$604M |
Cash Flow
| Metric | ACA | VATE |
|---|---|---|
| Operating Cash Flow | $341M | $141M |
| Free Cash Flow | $135M | $145M |
| Capital Spending | -$206M | $4M |
| OCF Growth YoY | -23.1% | 259.3% |
| FCF Growth YoY | -54.0% | 505.0% |
| FCF/Sales | 4.9% | 9.6% |
| CapEx/Sales | 7.5% | 0.3% |
Operational Efficiency
| Metric | ACA | VATE |
|---|---|---|
| Asset Turnover | 0.52x | 1.51x |
| Receivables Turnover | 4.9x | 5.3x |
| Inventory Turnover | 5.8x | 86.1x |
| Fixed Assets Turnover | 1.3x | 11.1x |
| Days Sales Outstanding | 74 days | 68 days |
| Days Inventory | 63 days | 4 days |
| Payables Period | 39 days | – |
| Cash Conversion Cycle | 99 days | – |
Income Statement
| Metric | ACA | VATE |
|---|---|---|
| Total Revenue | $2.74B | $1.52B |
| Operating Income | $323M | $65M |
| Net Income | $491M | -$22M |
| SG&A Expense | $325M | $161M |
| Cost of Goods Sold | $2.11B | $1.27B |
Dividend & Shareholder Information
| Metric | ACA | VATE |
|---|---|---|
| Dividends Per Share | $0.20 | $0.13 |
| Payout Ratio | 2.1% | – |
| Shares Outstanding | 49M | 14M |
| Net Income Growth | 433.0% | – |
| EPS Growth | 340.4% | – |
ACA vs VATE: stock comparison and AI forecast
Which is bigger, ACA or VATE?
ACA is 108.0 times larger than VATE by market capitalization ($7.32B against $68M).
Which one does Intratio's AI model rank higher, ACA or VATE?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.